Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals’ rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug’s safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.
The FDA has approved Daiichi Sankyo’s anti-clotting drug, edoxaban (Savaysa), as a once-daily treatment to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Roughly 50 million Americans take daily low-dose aspirin for cardioprevention, as it is generally perceived as a safe, effective, and inexpensive OTC preventive medication for cardiovascular disease. For patients who have nonvalvular atrial fibrillation, many guidelines recommend aspirin as thromboprophylaxis among those who are not considered to be high risk.
With proper treatment, individuals with atrial fibrillation can live normal and active lives.